Corcept Must Face Most Teva Mifepristone Antitrust Claims
A California federal judge on Tuesday once again mostly refused to throw out Teva Pharmaceuticals' claims that Corcept Therapeutics used patent system abuse, bribes and exclusive dealing to block generic competition...To view the full article, register now.
Already a subscriber? Click here to view full article